Phase 3 Trial of Janssen’s COVID-19 Vaccine to Evaluate Single Dose Regimen
A phase 3 trial evaluating the vaccine candidate, JNJ-78436735 (Ad26.COV2.S; Janssen), for the prevention of COVID-19 has been initiated.
A phase 3 trial evaluating the vaccine candidate, JNJ-78436735 (Ad26.COV2.S; Janssen), for the prevention of COVID-19 has been initiated.
Real-world, pre-COVID-19 adverse events data show hydroxychloroquine and chloroquine are associated with cardiovascular adverse events.
Researchers evaluated the performance of 2019 EULAR/ACR classification criteria for systemic lupus erythematosus, with regard to disease duration, sex, and race/ethnicity.
A new case of cutaneous lupus erythematosus or systemic lupus erythematosus could potentially be drug induced.
Researchers assessed the safety of hydroxychloroquine alone and in combination with azithromycin to determine the risk associated with its use in routine care in rheumatoid arthritis.
Pulmonary arterial compliance was found to be strongly associated with all-cause mortality and clinical worsening in patients with systemic lupus erythematosus-associated pulmonary arterial hypertension.
Researchers described the prevalence of self-reported frailty among patients with rheumatic musculoskeletal diseases and its associated factors.
Researchers evaluated the risk for ovarian dysfunction with cyclophosphamide use in women with severe lupus.
Patients with systematic lupus erythematosus who have a low platelet distribution width are more likely to have lupus nephritis.
Researchers investigated the effect of cosmetic camouflage on health-related quality of life in women with SLE and permanent facial skin damage.